Kura Oncology (KURA) Free Cash Flow (2010 - 2026)
Kura Oncology (KURA) reported Free Cash Flow of -$86.0 million for Q1 2026, down 19.06% year-over-year from -$106.2 million in Q1 2025, and down 176.32% quarter-over-quarter from $112.7 million in Q4 2025.
Kura Oncology (KURA) Free Cash Flow (2010 - 2026) Analysis & Trends
Kura Oncology (KURA) has 17 years of Free Cash Flow data on file, last reported at -$86.0 million in Q1 2026.
- Free Cash Flow for Q1 2026 came in at -$86.0 million, down 19.06% year-over-year; the trailing twelve-month figure through Mar 2026 was -$84.5 million (down 176.4% YoY), and the FY2025 annual result was -$70.7 million, down 152.82% from the prior year.
- Free Cash Flow declined to -$86.0 million in Q1 2026 per KURA's latest filing, from $112.7 million in the prior quarter.
- Over five years, Free Cash Flow peaked at $268.8 million in Q4 2024 and troughed at -$86.0 million in Q1 2026.
- A 5-year average of -$15.2 million and a median of -$32.2 million in 2022 frame the typical range for Free Cash Flow.
- The sharpest annual moves came in 2024 and 2025: Free Cash Flow surged 883.01% in 2024, then sank 86.24% in 2025.
- A 5-year view of Free Cash Flow shows it stood at -$26.5 million in 2022, then dropped by 29.32% to -$34.3 million in 2023, then surged by 883.01% to $268.8 million in 2024, then tumbled by 58.08% to $112.7 million in 2025, then plunged by 176.32% to -$86.0 million in 2026.
- Business Quant data shows KURA's Free Cash Flow at -$86.0 million in Q1 2026, $112.7 million in Q4 2025, and -$80.9 million in Q3 2025.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Free Cash Flow (Qtr) |
|---|---|---|---|---|---|
| 1 | Alterity Therapeutics | 925,601.88 Bn | 925,601.85 Bn | - | - |
| 2 | Belite Bio | 58,560.00 Bn | 58,560.00 Bn | - | - |
| 3 | Quantum Biopharma | 17,284.41 Bn | 17,284.40 Bn | - | -1.67 Mn |
| 4 | Legend Biotech | 2,809.00 Bn | 2,808.71 Bn | 242.10 Mn | -12.20 Mn |
| 5 | Evaxion A | 1,334.43 Bn | 1,334.42 Bn | - | - |
| 6 | Akari Therapeutics | 1,312.27 Bn | 1,312.26 Bn | - | -2.49 Mn |
| 7 | Psyence Biomedical | 212.16 Bn | 212.16 Bn | - | - |
| 8 | Vertex Pharmaceuticals | 114.83 Bn | 107.58 Bn | 2.59 Bn | 1.29 Bn |
| 9 | Abivax | 91.96 Bn | 91.96 Bn | - | 63,220.27 |
| 10 | Kura Oncology | 883.44 Mn | 883.44 Mn | 18.00 Mn | -85.98 Mn |
Historic Data
Download Data| Date | Value |
|---|---|
| Mar 31, 2026 | -85.98 Mn |
| Mar 31, 2026 | -85.98 Mn |
| Dec 31, 2025 | 112.66 Mn |
| Dec 31, 2025 | 112.66 Mn |
| Sep 30, 2025 | -80.90 Mn |
| Sep 30, 2025 | -80.90 Mn |
| Jun 30, 2025 | -30.24 Mn |
| Jun 30, 2025 | -30.24 Mn |
| Mar 31, 2025 | -72.22 Mn |
| Mar 31, 2025 | -72.22 Mn |
| Dec 31, 2024 | 268.76 Mn |
| Dec 31, 2024 | 268.76 Mn |
| Sep 30, 2024 | -43.44 Mn |
| Sep 30, 2024 | -43.44 Mn |
| Jun 30, 2024 | -42.55 Mn |
| Jun 30, 2024 | -42.55 Mn |
| Mar 31, 2024 | -48.93 Mn |
| Mar 31, 2024 | -48.93 Mn |
| Dec 31, 2023 | -34.32 Mn |
| Dec 31, 2023 | -34.32 Mn |